Add Formweb to your mobile device
Following is a P and T Committee update (from the October 23rd meeting). Starting date for specific programs is 23 Oct 2018, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red.
Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.
|
Drug or Drug Class |
Formulary Decision |
Comments |
| insulin lispro (Admelog) |
Non-Formulary Automatic Substitution Approved |
Ademlog is a biosimilar of Humalog. Orders for Ademlog should be converted to Humalog at a 1:1 dosage ratio. |
| semaglutide (Ozempic) | Non-Formulary | Inpatients may use home supply. Alternatively, the formulary agent, liraglutide, is a GLP-1 receptor agonist available for inpatient use. |
| ibalizumab-uiyk (Trogarzo) | Non-Formulary | Very rare use expected in our region. |
| erenumab-aooe (Aimovig) | Non-Formulary | Inpatients may use home supply. |
| iloperidone (Fanapt) Update |
Reclassified as Formulary, Restricted
|
Restricted to continuation of maintenance therapy. Due to rare use and drug waste, patients will not be started on the initial titration regimens in the hospital. 1 mg and 2 mg strengths will not be stocked. 4 mg and 6 mg tablets can be utilized (not routinely stocked) for continuation of therapy upon admission. |
| tolvaptan (Jynarque) | Non-Formulary | Inpatients may use home supply. Nephrology consult is recommended. Samsca should not be dispensed for Jynarque orders. |
| fish oil triglycerides (Omegaven) Injectable Emulsion | Formulary, Restricted | Restricted to use in pediatric patients with a direct or conjugated bilirubin level of ≥ 2 mg/dL who are expected to be on parenteral nutrition for at least 2 weeks. |
| Liposomal Bupivacaine (Exparel) High Value Care Committee Report | Reclassified as Non-Formulary | Non-Formulary status takes effect January 1, 2019. |
| Pediatric Code Care Weight Based Dosing Update | Updates Approved | Pediatric dosing charts can be accessed from the Pulse Page. |
| PRN Range Orders During Cerner Conversion | Process Approved | During the initial conversion from iCare to Cerner, medication profiles with range orders (dosage, dosage form, or frequency) may be automatically adjusted by the pharmacist following the approved processes. |